Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis

Recommendations from PancreasFest 2012

Michael R. Rickels, Melena Bellin, Frederico G S Toledo, R. Paul Robertson, Dana K. Andersen, Suresh T. Chari, Randall Brand, Luca Frulloni, Michelle A. Anderson, David C. Whitcomb

Research output: Contribution to journalArticle

Abstract

Description: Diabetes and glucose intolerance are common complications of chronic pancreatitis, yet clinical guidance on their detection, classification, and management is lacking. Methods: A working group reviewed the medical problems, diagnostic methods, and treatment options for chronic pancreatitis-associated diabetes for a consensus meeting at PancreasFest 2012. Results: Guidance Statement 1.1: Diabetes mellitus is common in chronic pancreatitis.While any patient with chronic pancreatitis should be monitored for development of diabetes, those with long-standing duration of disease, prior partial pancreatectomy, and early onset of calcific disease may be at higher risk. Those patients developing diabetes mellitus are likely to have co-existing pancreatic exocrine insufficiency. Guidance Statement 1.2: Diabetes occurring secondary to chronic pancreatitis should be recognized as pancreatogenic diabetes (type 3c diabetes). Guidance Statement 2.1: The initial evaluation should include fasting glucose and HbA1c. These tests should be repeated annually. Impairment in either fasting glucose or HbA1c requires further evaluation. Guidance Statement 2.2: Impairment in either fasting glucose or HbA1c should be further evaluated by a standard 75 g oral glucose tolerance test. Guidance Statement 2.3: An absent pancreatic polypeptide response to mixed-nutrient ingestion is a specific indicator of type 3c diabetes. Guidance Statement 2.4: Assessment of pancreatic endocrine reserve, and importantly that of functional beta-cell mass, should be performed as part of the evaluation and follow-up for total pancreatectomy with islet autotransplantation (TPIAT). Guidance Statement 3: Patients with pancreatic diabetes shall be treated with specifically tailored medical nutrition and pharmacologic therapies. Conclusions: Physicians should evaluate and treat glucose intolerance in patients with pancreatitis.

Original languageEnglish (US)
Pages (from-to)336-342
Number of pages7
JournalPancreatology
Volume13
Issue number4
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Chronic Pancreatitis
Diabetes Mellitus
Fasting
Pancreatectomy
Glucose Intolerance
Glucose
Nutrition Therapy
Exocrine Pancreatic Insufficiency
Therapeutics
Pancreatic Polypeptide
Autologous Transplantation
Glucose Tolerance Test
Pancreatitis
Consensus
Eating
Physicians
Food

Keywords

  • Chronic pancreatitis
  • Diabetes mellitus
  • GLP-1
  • Glucose tolerance test
  • Incretin
  • Insulin
  • Pancreatic polypeptide
  • Pancreatogenic diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology

Cite this

Rickels, M. R., Bellin, M., Toledo, F. G. S., Robertson, R. P., Andersen, D. K., Chari, S. T., ... Whitcomb, D. C. (2013). Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012. Pancreatology, 13(4), 336-342. https://doi.org/10.1016/j.pan.2013.05.002

Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis : Recommendations from PancreasFest 2012. / Rickels, Michael R.; Bellin, Melena; Toledo, Frederico G S; Robertson, R. Paul; Andersen, Dana K.; Chari, Suresh T.; Brand, Randall; Frulloni, Luca; Anderson, Michelle A.; Whitcomb, David C.

In: Pancreatology, Vol. 13, No. 4, 07.2013, p. 336-342.

Research output: Contribution to journalArticle

Rickels, MR, Bellin, M, Toledo, FGS, Robertson, RP, Andersen, DK, Chari, ST, Brand, R, Frulloni, L, Anderson, MA & Whitcomb, DC 2013, 'Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012', Pancreatology, vol. 13, no. 4, pp. 336-342. https://doi.org/10.1016/j.pan.2013.05.002
Rickels, Michael R. ; Bellin, Melena ; Toledo, Frederico G S ; Robertson, R. Paul ; Andersen, Dana K. ; Chari, Suresh T. ; Brand, Randall ; Frulloni, Luca ; Anderson, Michelle A. ; Whitcomb, David C. / Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis : Recommendations from PancreasFest 2012. In: Pancreatology. 2013 ; Vol. 13, No. 4. pp. 336-342.
@article{c99f791340f44d9499759bfcefe40b9e,
title = "Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012",
abstract = "Description: Diabetes and glucose intolerance are common complications of chronic pancreatitis, yet clinical guidance on their detection, classification, and management is lacking. Methods: A working group reviewed the medical problems, diagnostic methods, and treatment options for chronic pancreatitis-associated diabetes for a consensus meeting at PancreasFest 2012. Results: Guidance Statement 1.1: Diabetes mellitus is common in chronic pancreatitis.While any patient with chronic pancreatitis should be monitored for development of diabetes, those with long-standing duration of disease, prior partial pancreatectomy, and early onset of calcific disease may be at higher risk. Those patients developing diabetes mellitus are likely to have co-existing pancreatic exocrine insufficiency. Guidance Statement 1.2: Diabetes occurring secondary to chronic pancreatitis should be recognized as pancreatogenic diabetes (type 3c diabetes). Guidance Statement 2.1: The initial evaluation should include fasting glucose and HbA1c. These tests should be repeated annually. Impairment in either fasting glucose or HbA1c requires further evaluation. Guidance Statement 2.2: Impairment in either fasting glucose or HbA1c should be further evaluated by a standard 75 g oral glucose tolerance test. Guidance Statement 2.3: An absent pancreatic polypeptide response to mixed-nutrient ingestion is a specific indicator of type 3c diabetes. Guidance Statement 2.4: Assessment of pancreatic endocrine reserve, and importantly that of functional beta-cell mass, should be performed as part of the evaluation and follow-up for total pancreatectomy with islet autotransplantation (TPIAT). Guidance Statement 3: Patients with pancreatic diabetes shall be treated with specifically tailored medical nutrition and pharmacologic therapies. Conclusions: Physicians should evaluate and treat glucose intolerance in patients with pancreatitis.",
keywords = "Chronic pancreatitis, Diabetes mellitus, GLP-1, Glucose tolerance test, Incretin, Insulin, Pancreatic polypeptide, Pancreatogenic diabetes",
author = "Rickels, {Michael R.} and Melena Bellin and Toledo, {Frederico G S} and Robertson, {R. Paul} and Andersen, {Dana K.} and Chari, {Suresh T.} and Randall Brand and Luca Frulloni and Anderson, {Michelle A.} and Whitcomb, {David C.}",
year = "2013",
month = "7",
doi = "10.1016/j.pan.2013.05.002",
language = "English (US)",
volume = "13",
pages = "336--342",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis

T2 - Recommendations from PancreasFest 2012

AU - Rickels, Michael R.

AU - Bellin, Melena

AU - Toledo, Frederico G S

AU - Robertson, R. Paul

AU - Andersen, Dana K.

AU - Chari, Suresh T.

AU - Brand, Randall

AU - Frulloni, Luca

AU - Anderson, Michelle A.

AU - Whitcomb, David C.

PY - 2013/7

Y1 - 2013/7

N2 - Description: Diabetes and glucose intolerance are common complications of chronic pancreatitis, yet clinical guidance on their detection, classification, and management is lacking. Methods: A working group reviewed the medical problems, diagnostic methods, and treatment options for chronic pancreatitis-associated diabetes for a consensus meeting at PancreasFest 2012. Results: Guidance Statement 1.1: Diabetes mellitus is common in chronic pancreatitis.While any patient with chronic pancreatitis should be monitored for development of diabetes, those with long-standing duration of disease, prior partial pancreatectomy, and early onset of calcific disease may be at higher risk. Those patients developing diabetes mellitus are likely to have co-existing pancreatic exocrine insufficiency. Guidance Statement 1.2: Diabetes occurring secondary to chronic pancreatitis should be recognized as pancreatogenic diabetes (type 3c diabetes). Guidance Statement 2.1: The initial evaluation should include fasting glucose and HbA1c. These tests should be repeated annually. Impairment in either fasting glucose or HbA1c requires further evaluation. Guidance Statement 2.2: Impairment in either fasting glucose or HbA1c should be further evaluated by a standard 75 g oral glucose tolerance test. Guidance Statement 2.3: An absent pancreatic polypeptide response to mixed-nutrient ingestion is a specific indicator of type 3c diabetes. Guidance Statement 2.4: Assessment of pancreatic endocrine reserve, and importantly that of functional beta-cell mass, should be performed as part of the evaluation and follow-up for total pancreatectomy with islet autotransplantation (TPIAT). Guidance Statement 3: Patients with pancreatic diabetes shall be treated with specifically tailored medical nutrition and pharmacologic therapies. Conclusions: Physicians should evaluate and treat glucose intolerance in patients with pancreatitis.

AB - Description: Diabetes and glucose intolerance are common complications of chronic pancreatitis, yet clinical guidance on their detection, classification, and management is lacking. Methods: A working group reviewed the medical problems, diagnostic methods, and treatment options for chronic pancreatitis-associated diabetes for a consensus meeting at PancreasFest 2012. Results: Guidance Statement 1.1: Diabetes mellitus is common in chronic pancreatitis.While any patient with chronic pancreatitis should be monitored for development of diabetes, those with long-standing duration of disease, prior partial pancreatectomy, and early onset of calcific disease may be at higher risk. Those patients developing diabetes mellitus are likely to have co-existing pancreatic exocrine insufficiency. Guidance Statement 1.2: Diabetes occurring secondary to chronic pancreatitis should be recognized as pancreatogenic diabetes (type 3c diabetes). Guidance Statement 2.1: The initial evaluation should include fasting glucose and HbA1c. These tests should be repeated annually. Impairment in either fasting glucose or HbA1c requires further evaluation. Guidance Statement 2.2: Impairment in either fasting glucose or HbA1c should be further evaluated by a standard 75 g oral glucose tolerance test. Guidance Statement 2.3: An absent pancreatic polypeptide response to mixed-nutrient ingestion is a specific indicator of type 3c diabetes. Guidance Statement 2.4: Assessment of pancreatic endocrine reserve, and importantly that of functional beta-cell mass, should be performed as part of the evaluation and follow-up for total pancreatectomy with islet autotransplantation (TPIAT). Guidance Statement 3: Patients with pancreatic diabetes shall be treated with specifically tailored medical nutrition and pharmacologic therapies. Conclusions: Physicians should evaluate and treat glucose intolerance in patients with pancreatitis.

KW - Chronic pancreatitis

KW - Diabetes mellitus

KW - GLP-1

KW - Glucose tolerance test

KW - Incretin

KW - Insulin

KW - Pancreatic polypeptide

KW - Pancreatogenic diabetes

UR - http://www.scopus.com/inward/record.url?scp=84884700278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884700278&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2013.05.002

DO - 10.1016/j.pan.2013.05.002

M3 - Article

VL - 13

SP - 336

EP - 342

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 4

ER -